Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $407.03 | +0.11% | 374.8B | 31.06 | $13.29 | +2.15% |
| CVS | $97.53 | +0.46% | 123.8B | 42.56 | $2.28 | +2.74% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $404.86 | -3.18% | 92.2B | 17.99 | $23.60 | +1.61% |
| CI | $296.13 | +2.25% | 78B | 2.59 | $113.71 | +2.09% |
| HUM | $368.30 | +3.46% | 43.6B | 38.79 | $9.36 | +0.97% |
| CNC | $65.41 | +0.58% | 32.7B | -5.07 | -$13.05 | N/A |
| MOH | $196.39 | -1.02% | 10.6B | 54.58 | $3.72 | N/A |
| OSCR | $27.87 | +1.75% | 7.1B | -50.41 | -$0.54 | N/A |
Stock Comparison
GTS vs UNH Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 374.8B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $407.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 31.06. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs CVS Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 123.8B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $97.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 42.56. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs ANTM Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs ELV Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 92.2B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $404.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 17.99. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs CI Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 78B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $296.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 2.59. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.15%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs HUM Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 43.6B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $368.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 38.79. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.06%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 32.7B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $65.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is -5.07. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of -0.29%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 10.6B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $196.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 54.58. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs OSCR Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 7.1B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $27.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -50.41. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs ALHC Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 4B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is 192.00. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs CLOV Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 2.2B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -35.75. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.70%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs CABR Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CABR has a market cap of 18M. Regarding current trading prices, GTS is priced at $35.99, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CABR's P/E ratio is -1.77. In terms of profitability, GTS's ROE is +0.07%, compared to CABR's ROE of -3.00%. Regarding short-term risk, GTS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CABR's competition here
GTS vs BMGL Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is -1.45. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here
GTS vs MRAI Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 9.2M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.09. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.50%. Regarding short-term risk, GTS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here
GTS vs UAM Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UAM has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UAM's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to UAM's ROE of +0.17%. Regarding short-term risk, GTS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check UAM's competition here
GTS vs MGLN Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here
GTS vs AET Comparison June 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, AET has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas AET's P/E ratio is N/A. In terms of profitability, GTS's ROE is +0.07%, compared to AET's ROE of +0.11%. Regarding short-term risk, GTS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check AET's competition here